Clark Estates Inc. NY purchased a new position in ADMA Biologics Inc (NASDAQ:ADMA – Free Report) in the 3rd quarter, Holdings Channel reports. The firm purchased 278,000 shares of the biotechnology company’s stock, valued at approximately $2,788,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. NorthCrest Asset Manangement LLC increased its position in shares of ADMA Biologics by 8.4% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 15,952 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,234 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of ADMA Biologics by 4.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company’s stock valued at $319,000 after purchasing an additional 1,316 shares during the last quarter. Pinnacle Wealth Planning Services Inc. boosted its stake in ADMA Biologics by 33.1% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,422 shares during the last quarter. CenterBook Partners LP grew its holdings in shares of ADMA Biologics by 1.8% in the third quarter. CenterBook Partners LP now owns 81,607 shares of the biotechnology company’s stock valued at $819,000 after purchasing an additional 1,432 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of ADMA Biologics by 0.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 395,356 shares of the biotechnology company’s stock worth $3,309,000 after buying an additional 1,705 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.
Insider Buying and Selling at ADMA Biologics
In related news, Director Lawrence Guiheen sold 10,000 shares of the firm’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $13.92, for a total transaction of $139,200.00. Following the completion of the transaction, the director owned 63,599 shares of the company’s stock, valued at $885,298.08. This trade represents a 13.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.90% of the stock is owned by insiders.
ADMA Biologics Stock Up 1.2%
NASDAQ:ADMA opened at $13.63 on Wednesday. The company has a market cap of $3.02 billion, a PE ratio of 17.49 and a beta of 0.65. The company has a current ratio of 6.04, a quick ratio of 3.25 and a debt-to-equity ratio of 0.45. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46. The company’s 50 day moving average is $10.73 and its two-hundred day moving average is $10.76.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The firm had revenue of $141.10 million for the quarter, compared to the consensus estimate of $138.11 million. ADMA Biologics had a return on equity of 42.56% and a net margin of 35.14%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.15 EPS. Analysts anticipate that ADMA Biologics Inc will post 0.82 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on ADMA shares. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Cantor Fitzgerald increased their target price on shares of ADMA Biologics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Finally, Mizuho set a $18.00 price target on ADMA Biologics in a report on Thursday, November 5th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Moderate Buy” and a consensus price target of $17.50.
Read Our Latest Analysis on ADMA Biologics
ADMA Biologics Profile
ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.
Featured Articles
- Five stocks we like better than ADMA Biologics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA – Free Report).
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
